Cargando…

Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer

While there are no established pretreatment predictive and prognostic factors in patients with stage IIIA/pN2 non-small cell lung cancer (NSCLC) indicating a benefit to surgery as a part of trimodality approach, little is known about treatment-related predictive and prognostic factors in this settin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeremić, Branislav, Casas, Francesc, Dubinsky, Pavol, Gomez-Caamano, Antonio, Čihorić, Nikola, Videtic, Gregory, Igrutinovic, Ivan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829546/ https://www.ncbi.nlm.nih.gov/pubmed/29527511 http://dx.doi.org/10.3389/fonc.2018.00030

Ejemplares similares

Combined modality therapy in Stage IIIA non–small cell lung cancer: clarity or confusion despite the highest level of evidence?
por: Jeremic, Branislav, et al.
Publicado: (2017)

Radiation Therapy in Extensive Stage Small Cell Lung Cancer
por: Jeremic, Branislav, et al.
Publicado: (2017)

The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy
por: Yang, Hui, et al.
Publicado: (2021)

Select octogenarians with stage IIIa non–small cell lung cancer can benefit from trimodality therapy
por: Tang, Andrew, et al.
Publicado: (2022)

Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database
por: Cihoric, Nikola, et al.
Publicado: (2018)

Surgical Management of Stage IIIA Non-Small Cell Lung Cancer
por: Van Schil, Paul E., et al.
Publicado: (2017)

Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
por: Dan, Aravot, et al.
Publicado: (2019)

Correction to: Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
por: Aravot, Dan, et al.
Publicado: (2019)

Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer—results from a retrospective analysis
por: Joosten, Pieter J M, et al.
Publicado: (2021)

Human Papillomavirus-Related Non-Metastatic Oropharyngeal Carcinoma: Current Local Treatment Options and Future Perspectives
por: Svajdova, Michaela, et al.
Publicado: (2022)

Trimodality PET/CT/MRI and Radiotherapy: A Mini-Review
por: Decazes, Pierre, et al.
Publicado: (2021)

Re-Evaluation of the Survival Paradox Between Stage IIB/IIC and Stage IIIA Colon Cancer
por: Li, Hongbo, et al.
Publicado: (2020)

Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer
por: Turgeon, Guy-Anne, et al.
Publicado: (2014)

Lobectomy Versus Sublobectomy in Stage IIIA/N2 Non-Small Cell Lung Cancer: A Population-Based Study
por: Wang, Suyu, et al.
Publicado: (2021)

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
por: Li, Xin, et al.
Publicado: (2022)

Risk stratification of postoperative cardiopulmonary toxicity after trimodality therapy for esophageal cancer
por: Kowalchuk, Roman O., et al.
Publicado: (2023)

Skeletal muscle area predicts the outcomes of non-small-cell lung cancer after trimodality therapy
por: Watanabe, Kenji, et al.
Publicado: (2023)

Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer
por: Xie, Xiao-Hong, et al.
Publicado: (2021)

Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study
por: Dong, Daling, et al.
Publicado: (2023)

Tumor angiogenesis as an important prognostic factor in advanced non-small cell lung cancer (Stage IIIA)
por: Bačić, Ivan, et al.
Publicado: (2018)

Corrigendum: Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study
por: Dong, Daling, et al.
Publicado: (2023)

Trimodal Therapy vs. Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Meta-Analysis
por: Ding, Hui, et al.
Publicado: (2020)

Evaluation of Survival Outcomes With Trimodal Therapy as Primary Therapy for Non-organ-confined Bladder Cancer
por: Guo, Yadong, et al.
Publicado: (2019)

The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy
por: Yang, Hui, et al.
Publicado: (2021)

Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma
por: Goense, Lucas, et al.
Publicado: (2018)

Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report
por: Wang, Hongming, et al.
Publicado: (2023)

Characterization of positioning uncertainties in PET‐CT‐MR trimodality solutions for radiotherapy
por: Hinault, Pauline, et al.
Publicado: (2022)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy)
por: Aoki, Manabu, et al.
Publicado: (2014)

ER predicts poor prognosis in male lung squamous cell cancer of stage IIIA-N2 disease after sequential adjuvant chemoradiotherapy
por: Yang, Xue, et al.
Publicado: (2023)

Prognostic Value of Tumor Size in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer
por: Chen, Chih-Yu, et al.
Publicado: (2020)

Comprehensive Characterization of Stage IIIA Non-Small Cell Lung Carcinoma
por: Singh, Neetu, et al.
Publicado: (2020)

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
por: Lemmon, Christopher A., et al.
Publicado: (2022)

Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database
por: Cihoric, Nikola, et al.
Publicado: (2016)

Personalized trimodal prehabilitation for gastrectomy
por: Bausys, Augustinas, et al.
Publicado: (2020)

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
por: Chen, An-guo, et al.
Publicado: (2022)

Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report
por: Fu, Meng, et al.
Publicado: (2022)

Prognostic value of number of negative lymph node in patients with stage II and IIIa non-small cell lung cancer
por: Wang, Shengguang, et al.
Publicado: (2017)

The prognosis of clinical stage IIIa non‐small cell lung cancer in Taiwan
por: Cheng, Ya‐Fu, et al.
Publicado: (2023)

A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis
por: Sun, Shuang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p5bfke061j44gvbpnbkejlec80